The overall goal of this program project is to use transgenic and knockout mice to better understand selected aspects of the complex processes of lipoprotein metabolism and atherogenesis. The ability to manipulate the germ line of the mouse enables us to ask very specific questions about how relevant genes function in the body. It is also possible to reconstruct the mouse lipoprotein system by these genetic tools to mimic human dyslipoproteinemias and even to enhance atherosclerosis susceptibility. One example is our recent development of the apo E knockout mouse which accumulates high levels of cholesterol ester enriched lipoprotein remnants in plasma and develops extensive fibroproliferative human-like atherosclerotic lesions even on a low fat low cholesterol diet. Five projects and two cores are proposed. The projects entail studying: 1) cholesterol ester transfer protein gene regulation and function (Tall) 2) Lipoprotein lipase in lipoprotein metabolism, energy homeostasis, and atherogenesis (Breslow) 3) phospholipid transfer protein in lipoprotein metabolism and atherogenesis (Jiang) 4) altered macrophage phospholipid metabolism as a basis for foam cell necrosis (Tabas) 5) macrophage apo E gene expression and the ole of apo E in macrophage cholesterol metabolism as well as other macrophage functions which might play a role in atherogenesis (Smith). All of these projects make extensive use of the proposed transgenic core facility which will allow for the creation of new transgenic and knockout mice, crossbreeding genetically altered as well as naturally mutant mice, and embryo freezing. These projects will provide important new information about the genetic regulation of VLDL and HDL metabolism by lipases and lipid transfer proteins and how the genetic regulation of VLDL and HDL metabolism by lipases and lipid transfer proteins and how this might influence atherosclerosis susceptibility. They will also provide insight into aspects of macrophage biology such as macrophage LPL, apo E, and phospholipid metabolism which may be relevant to the formation and progression of atherosclerotic lesions. Overall, these studies are likely to contribute important new mechanistic information relevant to human dyslipidemia and atherogenesis.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Program Projects (P01)
Project #
1P01HL054591-01
Application #
2232976
Study Section
Heart, Lung, and Blood Initial Review Group (HLBP)
Project Start
1995-07-15
Project End
2000-06-30
Budget Start
1995-07-15
Budget End
1996-06-30
Support Year
1
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Rockefeller University
Department
Genetics
Type
Other Domestic Higher Education
DUNS #
071037113
City
New York
State
NY
Country
United States
Zip Code
10065
Fredman, Gabrielle; Kamaly, Nazila; Spolitu, Stefano et al. (2015) Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci Transl Med 7:275ra20
Libby, Peter; Tabas, Ira; Fredman, Gabrielle et al. (2014) Inflammation and its resolution as determinants of acute coronary syndromes. Circ Res 114:1867-79
Subramanian, Manikandan; Tabas, Ira (2014) Dendritic cells in atherosclerosis. Semin Immunopathol 36:93-102
Subramanian, Manikandan; Hayes, Crystal D; Thome, Joseph J et al. (2014) An AXL/LRP-1/RANBP9 complex mediates DC efferocytosis and antigen cross-presentation in vivo. J Clin Invest 124:1296-308
Nagareddy, Prabhakara R; Murphy, Andrew J; Stirzaker, Roslynn A et al. (2013) Hyperglycemia promotes myelopoiesis and impairs the resolution of atherosclerosis. Cell Metab 17:695-708
Subramanian, Manikandan; Thorp, Edward; Hansson, Goran K et al. (2013) Treg-mediated suppression of atherosclerosis requires MYD88 signaling in DCs. J Clin Invest 123:179-88
Gautier, Emmanuel L; Westerterp, Marit; Bhagwat, Neha et al. (2013) HDL and Glut1 inhibition reverse a hypermetabolic state in mouse models of myeloproliferative disorders. J Exp Med 210:339-53
Rodríguez, José M; Wolfrum, Susanne; Robblee, Megan et al. (2013) Altered expression of Raet1e, a major histocompatibility complex class 1-like molecule, underlies the atherosclerosis modifier locus Ath11 10b. Circ Res 113:1054-64
Tabas, Ira; Glass, Christopher K (2013) Anti-inflammatory therapy in chronic disease: challenges and opportunities. Science 339:166-72
Rong, James X; Blachford, Courtney; Feig, Jonathan E et al. (2013) ACAT inhibition reduces the progression of preexisting, advanced atherosclerotic mouse lesions without plaque or systemic toxicity. Arterioscler Thromb Vasc Biol 33:4-12

Showing the most recent 10 out of 124 publications